Patent ID: 11896614
Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 6:
7. The method of claim 6, wherein:
(a) one or more chemotherapy cycles or drugs are chosen from the group consisting of:
(i) vincristine, dexamethasone, PEG-L-asparaginase, daunorubicin;
(ii) vincristine, 6-mercaptopurine, cyclophosphamide, cytarabine, PEG-L-asparaginase;
(iii) vincristine, methotrexate, 6-mercaptopurine;
(iv) vincristine, dexamethasone, doxorubicin, PEG-L-asparaginase, cyclophosphamide, cytarabine, 6-thioguanine;
(v) vincristine, methotrexate, and
(vi) vincristine, dexamethasone, prednisone 6-mercaptopurine, methotrexate;

(b) the chemotherapy comprises a drug and dosing regimen for the treatment of subject classified as having standard-risk cancer is chosen from the group consisting of:
(i) vincristine 6 mg/m2, dexamethasone 6 mg/m2, PEG-L-asparaginase 2500 U/m2;
(ii) vincristine 1.5 mg/m2, 6-mercaptopurine 75 mg/m2;
(iii) vincristine 7.5 mg/m2, methotrexate 500 mg/m2;
(iv) vincristine 4.5 mg/m2, dexamethasone 10 mg/m2, doxorubicin 75 mg/m2, PEG-L-asparaginase 2500 U/m2, cyclophosphamide 1 g/m2, cytarabine 60 mg/m2, 6-thioguanine 60 mg/m2;
(v) vincristine 7.5 mg/m2, methotrexate 500 mg/m2; and
(vi) vincristine 1.5 mg/m2, dexamethasone 6 mg/m2, 6-mercaptopurine 75 mg/m2, methotrexate 20 mg/m2;

(c) the chemotherapy comprises a drug and dosing regimen for the treatment of subject classified as having high-risk cancer is chosen from the group consisting of:
(i) vincristine 6 mg/m2, dexamethasone 6 mg/m2, PEG-L-asparaginase 2500 U/m2, daunorubicin 100 mg/m2;
(ii) vincristine 1.5 mg/m2, 6-mercaptopurine 60 mg/m2, cyclophosphamide 1 g/m2, cytarabine 75 mg/m2, PEG-L-asparaginase 2500 mg/m2;
(iii) vincristine 7.5 mg/m2, methotrexate 20 mg/m2, 6-mercaptopurine 25 mg/m2;
(iv) vincristine 7.5 mg/m2, dexamethasone 10 mg/m2, doxorubicin 75 mg/m2, PEG-L-asparaginase 5000 U/m2, cyclophosphamide 1 g/m2, cytarabine 60 mg/m2, 6-thioguanine 60 mg/m2; and
(v) vincristine 1.5 mg/m2, prednisone 40 mg/m2, 6-mercaptopurine 75 mg/m2, methotrexate 20 mg/m2; or

(d) the chemotherapy comprises one or more of vincristine, dexamethasone, PEG-L-asparaginase, daunorubicin, 6-mercaptopurine, cyclophosphamide, cytarabine, methotrexate, doxorubicin, 6-thioguanine, and prednisone.